Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02482441
Title A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Rosmantuzumab

Fluorouracil + Irinotecan + Leucovorin

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UCSF San Francisco California 95115 United States Details
University of Colorado Hospital Anschulz Cancer Pavilion Aurora Colorado 80045 United States Details
Yale New Haven Connecticut 06520-8028 United States Details
Massachusetts General Hospital, Dana Farber Cancer Institute Boston Massachusetts 02114 United States Details
Duke University Durham North Carolina 27710 United States Details
The Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
M.D. Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field